Adagrasib is an oral, small-molecule anticancer drug that serves as a selective inhibitor of the mutated KRAS G12C protein, a key driver of tumor growth in various malignancies, including non-small cell… Read more








Adagrasib is an oral, small-molecule anticancer drug that serves as a selective inhibitor of the mutated KRAS G12C protein, a key driver of tumor growth in various malignancies, including non-small cell lung cancer and colorectal cancer. As laboratories engage in rigorous analytical testing and quality control for this potent pharmaceutical, high-quality reference standards are essential to ensure the safety and efficacy of the drug substance. This category provides a comprehensive selection of Adagrasib materials, including pharmacopeial and non-pharmacopeial impurities, such as nitroso derivatives and related synthetic intermediates. Additionally, the list features stable isotope labelled compounds, which are critical for impurity profiling and method validation. These research tools support precise identification and quantification, enabling scientists to maintain strict regulatory compliance throughout the development and manufacturing processes of this targeted therapeutic.